- ISIN: US0191141078
- Land: .
Nachricht vom 23.09.2019 | 12:03
Allied Corp. Files First US Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder
DGAP-News: Allied Corp.
/ Key word(s): Miscellaneous
Kelowna, British Columbia--(Newsfile Corp. - September 23, 2019) - Allied Corp. ("Allied") (OTC PINK: ALID) - an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today's medical issues - is pleased to announce the filing of its first United States Provisional Patent Application for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD).
This marks the first of a series of proposed filings, along with recent trademark filings, as part of the Company's Intellectual Property and Pharma Development (IP&PD) Strategy. This Pharma Development Strategy includes serving those suffering from mental health issues, with a particular focus on those suffering from symptoms related to PTSD.
The products developed under the Company's IP&PD strategy are initially geared towards veterans and first responders and will further be available to anyone else suffering from symptoms related to PTSD. These products will be made available for sale under Allied's recently launched natural health hemp-derived retail product line, TACTICAL RELIEF™.
"We are very excited to begin taking the strategic steps to developing and protecting our IP&PD strategy in the United States and around the world," said David Weinkauf, VP Pharma Development. "Allied is committed to the development of a thoughtful and strategic Intellectual Property portfolio that is strengthened internationally by this filing."
Allied is dedicated to promoting a holistic approach to healing that reinforces a specialized model of care. The model's main goal is to assist in preventing suicides among veterans and first responders who are suffering from PTSD or other disorders related to mental health.
"Currently, there are approximately 8 million people in the United States alone who suffer from symptoms related to PTSD. Although there are certain cognitive therapies that have proven to be helpful, there is no pharmaceutical drug that has an indication for this disease target. PTSD is a disorder that not only affects the person suffering, but his/her family and community as well. Through this patent filing, we have now taken the first step in our pharma development plan, as well as, protected our medical formulation that is focused on this disease target." says Calum Hughes, CEO, Allied Corp.
For more information on Allied Corp., visit www.allied.health
About Allied Corp.
Allied Corp. is an international medical cannabis production company with a mission to address today's medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.
This news release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or future performance. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as "anticipate", "become", "objective", "may", "will", "might", "should", "could", "can", "intend", "expect", "believe", "estimate", "predict", "potential", "plan", "is designed to", "project", "continue", or similar expressions suggest future outcomes or the negative thereof or similar variations. Such forward-looking statements include, but are not limited to, that the Company will receive its US Patent for Cannabinoid and Terpenoid Pharmaceutical Compositions and Methods for Treating Post-Traumatic Stress Disorder (PTSD) and that the Company's proposed hemp-derived retail product line, TACTICAL RELIEF™, will be accepted by service members and first responders. We are also subject to various additional risks as described in our SEC filings at www.SEC.gov.
Forward-looking statements are based on management's current expectations and may materially differ from actual results. Further, such forward-looking statements are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48017
Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/48017
News Source: Newsfile
|EQS News ID:||877999|
|End of News||DGAP News Service|
Interview im Fokus
„Im europäischen Spitzenfeld der Private-Equity-Liga“
Die Münchner Private-Equity-Gesellschaft Mutares (ISIN: DE000A2NB650) ist mit bereits fünf Akquisitionen in 2020 erneut mit einem hohen Wachstumstempo unterwegs. Im Exklusivinterview mit Financial.de verraten die Vorstände Robin Laik (CEO) und Johannes Laumann (CIO), wie man sich bei den jüngsten Deals gegen die Konkurrenz durchgesetzt hat, wie man einen Return auf das eingesetzte Kapital von 7 bis 10 erreichen will und warum sich Mutares-Aktionäre auch für 2020 auf eine attraktive Dividende freuen dürfen.
Event im Fokus
Fachkonferenz Beteiligungsgesellschaften, 15.07.2020
Fachkonferenz Consumer / Leisure, 16.07.2020
Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.
Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv
Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.
Der AKTIONÄR News
15. Juli 14:48 Linde: So stark wie nie zuvor
15. Juli 14:25 NetCents-Aktie: Ohne News nix los
News im Fokus
HeidelbergCement AG: Vorläufiges Ergebnis von HeidelbergCement im zweiten Quartal 2020 über Markterwartungen
14. Juli 2020, 16:38
Webcast TeamViewer acquires Ubimax
15. Juli 2020
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
15. Juli 2020